You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma

Citation Tools

Article menu

Download PDFPDF

Oral Abstracts
Opening Ceremony and Plenary 1: Oral Abstract Presentations
O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Tewari K, Monk B, Vergote I, et al
O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma
International Journal of Gynecologic Cancer 2021;31:A1.